Replies to post #122057 on Biotech Values

[DewDiligence]

OXGN’s IV data in AMD or cancer was not as good as squalamine, so I wouldn't expect it to work through the eye.

Actually, intravenous CA4P had some activity in myopic macular denegation (a cousin of AMD), but it was too toxic for a non-life-threatening condition.

To reiterate, the result you are hoping for—a drug administered by eye drops that is effective at treating retinal disease—is almost impossible due to the physiology of the eye. Any bioetch company that is working on such a program is almost certainly a scam.